Alkermes: Q3 Earnings Snapshot
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- ALKS Alkermes+1.8% 6d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Alkermes belongs to, so it often moves with news about it.
- NVS Novartis AG-1.9% 9d
Novartis AG is a peer of Alkermes in pharmaceutical preparations; rivals often move on the same news.
- AZN AstraZeneca+14.8% 30d
AstraZeneca is a peer of Alkermes in pharmaceutical preparations; rivals often move on the same news.
- NVO Novo Nordisk A/S+0.1% 30d
Novo Nordisk A/S is a peer of Alkermes in pharmaceutical preparations; rivals often move on the same news.
- GSK Gsk+0.7% 5d
Gsk is a peer of Alkermes in pharmaceutical preparations; rivals often move on the same news.
- SNY Sanofi
Sanofi is a peer of Alkermes in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| ALKS | -1.20% | +1.18% | base | +1.85% | +2.36% | -0.69% | +2.35% |
| XLV | -2.95% | -0.31% | base | -0.34% | +2.73% | +0.31% | +0.13% |
| NVS | -2.88% | -0.25% | base | -1.37% | +2.20% | +0.20% | +0.73% |
| AZN | -8.84% | -6.48% | base | -1.45% | +1.29% | +0.31% | -0.09% |
| NVO | -4.41% | -3.21% | base | -0.61% | +4.24% | -0.96% | -0.38% |
| GSK | +3.75% | -0.94% | base | -0.79% | +4.11% | +2.52% | +2.42% |
| SNY | -7.99% | -5.28% | base | -0.45% | +4.20% | +2.65% | +3.25% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Alkermes: Q3 Earnings Snapshot Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| ALKS | that day | +1.85% | final price |
| ALKS | the next day | +2.36% | final price |
| ALKS | two days later | -0.69% | final price |
| ALKS | three days later | +2.35% | final price |
| ALKS | three days earlier | +1.18% | final price |
| ALKS | five days earlier | -1.20% | final price |
| AZN | that day | -1.45% | final price |
| AZN | the next day | +1.29% | final price |
| AZN | two days later | +0.31% | final price |
| AZN | three days later | -0.09% | final price |
| AZN | three days earlier | -6.48% | final price |
| AZN | five days earlier | -8.84% | final price |
| GSK | that day | -0.79% | final price |
| GSK | the next day | +4.11% | final price |
| GSK | two days later | +2.52% | final price |
| GSK | three days later | +2.42% | final price |
| GSK | three days earlier | -0.94% | final price |
| GSK | five days earlier | +3.75% | final price |
| NVO | that day | -0.61% | final price |
| NVO | the next day | +4.24% | final price |
| NVO | two days later | -0.96% | final price |
| NVO | three days later | -0.38% | final price |
| NVO | three days earlier | -3.21% | final price |
| NVO | five days earlier | -4.41% | final price |
| NVS | that day | -1.37% | final price |
| NVS | the next day | +2.20% | final price |
| NVS | two days later | +0.20% | final price |
| NVS | three days later | +0.73% | final price |
| NVS | three days earlier | -0.25% | final price |
| NVS | five days earlier | -2.88% | final price |
| SNY | that day | -0.45% | final price |
| SNY | the next day | +4.20% | final price |
| SNY | two days later | +2.65% | final price |
| SNY | three days later | +3.25% | final price |
| SNY | three days earlier | -5.28% | final price |
| SNY | five days earlier | -7.99% | final price |
| XLV | that day | -0.34% | final price |
| XLV | the next day | +2.73% | final price |
| XLV | two days later | +0.31% | final price |
| XLV | three days later | +0.13% | final price |
| XLV | three days earlier | -0.31% | final price |
| XLV | five days earlier | -2.95% | final price |
Congressional trades in the stocks in this story
- Rep. Gilbert Cisneros bought Alkermes (ALKS), worth $1,001 - $15,000 on 29 Sep 2026. That is 35 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Kevin Hern sold Novartis Ag (NVS), worth $15,001 - $50,000 on 27 Aug 2026. That is 68 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 10 Sep 2026. That is 54 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 31 Aug 2026. That is 64 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Scott Scott Franklin bought Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 26 Aug 2026. That is 69 days before publication. Filed 17 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “Alkermes: Q3 Earnings Snapshot” looks
12 out of 100
“Alkermes: Q3 Earnings Snapshot” scores 12 out of 100. The score uses 1 sources.